TY - JOUR
T1 - Therapeutic Strategies in the Development of Anti-viral Drugs and Vaccines Against SARS-CoV-2 Infection
AU - Bhatti, Jasvinder Singh
AU - Bhatti, Gurjit Kaur
AU - Khullar, Naina
AU - Reddy, Arubala P.
AU - Reddy, P. Hemachandra
N1 - Funding Information:
The research presented in this article was supported by the National Institutes of Health (NIH) grants AG042178, AG047812, NS105473, AG060767, and AG069333 (to PHR). This research was also supported by the Alzheimer’s Association New Investigator Research Grant 2016-NIRG-39787, the Center of Excellence for Translational Neuroscience and Therapeutics (PN-CTNT20115-AR), Alzheimer’s Association through a SAGA grant, and NIH grant AG063162 (to AR). We acknowledge support from the Central University of Punjab, Bathinda, India. We thank all the doctors, nurses, health workers, and research scientists who are working day and night to fight against the COVID-19 pandemic. The figures were assembled using dynamic BioRender assets.
Publisher Copyright:
© 2020, Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2020/11/1
Y1 - 2020/11/1
N2 - The whole world is currently facing a pandemic of an infectious disease known as novel coronavirus disease-2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) . This outbreak emerged unexpectedly and imposed a potential threat to humans, associated with the social and economic burden on the individual and federal governments. COVID-19, which initially started in Wuhan City of China and then spread to the whole world, has been declared a Public Health Emergency of International Concern. The continuous increase in the number of confirmed cases leads to high mortality across the world. Growing evidence indicates that the mortality rate is very predominant in elderly people and those with preexisting health conditions. However, the potential pathogenesis of SARS-CoV-2 infection in humans is still unknown. The dysregulated/exuberant immune response may have substantially contributed to the SARS-CoV-2-mediated pathology. Nevertheless, there is no clinically approved drug/vaccine currently available that can restrict its pathogenesis. However, several drugs are currently shown to provide some therapeutic benefits for COVID-19 patients, including antiviral drugs that might have a significant role in restricting the current pandemic of COVID-19. In this article, we highlighted the pharmacological treatment strategies for COVID-19 and purposed the therapeutic targets for the development of vaccines or anti-viral drug molecules against SARS-CoV-2 infection in humans.
AB - The whole world is currently facing a pandemic of an infectious disease known as novel coronavirus disease-2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) . This outbreak emerged unexpectedly and imposed a potential threat to humans, associated with the social and economic burden on the individual and federal governments. COVID-19, which initially started in Wuhan City of China and then spread to the whole world, has been declared a Public Health Emergency of International Concern. The continuous increase in the number of confirmed cases leads to high mortality across the world. Growing evidence indicates that the mortality rate is very predominant in elderly people and those with preexisting health conditions. However, the potential pathogenesis of SARS-CoV-2 infection in humans is still unknown. The dysregulated/exuberant immune response may have substantially contributed to the SARS-CoV-2-mediated pathology. Nevertheless, there is no clinically approved drug/vaccine currently available that can restrict its pathogenesis. However, several drugs are currently shown to provide some therapeutic benefits for COVID-19 patients, including antiviral drugs that might have a significant role in restricting the current pandemic of COVID-19. In this article, we highlighted the pharmacological treatment strategies for COVID-19 and purposed the therapeutic targets for the development of vaccines or anti-viral drug molecules against SARS-CoV-2 infection in humans.
KW - Anti-viral drugs
KW - COVID-19
KW - Clinical trials
KW - Novel coronavirus disease
KW - SARS-CoV-2
KW - Vaccine
UR - http://www.scopus.com/inward/record.url?scp=85089485741&partnerID=8YFLogxK
U2 - 10.1007/s12035-020-02074-2
DO - 10.1007/s12035-020-02074-2
M3 - Review article
C2 - 32808122
AN - SCOPUS:85089485741
VL - 57
SP - 4856
EP - 4877
JO - Molecular Neurobiology
JF - Molecular Neurobiology
SN - 0893-7648
IS - 11
ER -